Tenormin

Quick links to important sections

Tenormin

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tenormin

Tenormin (Atenolol) Overview

Tenormin is the original trade name for the prescription medicine containing the active ingredient atenolol. It is a synthetic compound classified as a beta-adrenergic receptor antagonist, commonly referred to as a beta blocker. This classification identifies it as an agent used to influence and stabilize activity within the cardiovascular system to manage heart function.


Definition and Pharmacological Class

Atenolol is a cardioselective beta blocker, meaning it preferentially targets and blocks the beta1 receptors located primarily in the heart. This selective action is a defining feature of this second-generation agent. The medication is used to treat conditions involving the heart and blood vessels. This focused effect offers a specific influence on cardiac function compared to non-selective agents. Atenolol is available as a prescription-only medication.


Composition, Origin, and Available Forms

The medication is a single-entity product consisting of atenolol. The drug’s hydrophilic nature is a compositional feature that influences its distribution within the body. While manufactured as an oral tablet for long-term therapeutic regimens, the medication is also produced as an intravenous solution for injection. These different formats provide options for both immediate and ongoing care.


General Purpose of Atenolol (Tenormin)

The general purpose of Atenolol is to reduce the overall workload of the heart and exert a regulating effect on the circulatory system. By acting as an antagonist, it lowers the heart's exposure to stimulating stress hormones, which leads to a decrease in both the speed and force of cardiac contractions. This reduction in cardiac strain supports the management of high blood pressure and is used for stabilizing the heart's rhythm in cases of cardiovascular strain.

What side effects are possible with Tenormin?

The official safety documentation for atenolol (Tenormin) outlines adverse reactions based on their frequency and the body system affected, as classified by government regulatory authorities.

Frequency and System-Organ Classification

Common adverse reactions (occurring in at least 1% of patients) typically involve the cardiovascular and nervous systems, including officially listed instances of bradycardia (slow heart rate), fatigue, and cold extremities. Gastrointestinal disturbances, such as nausea and diarrhea, are also classified as common effects. Uncommon reactions include sleep disturbances and mood changes.

Rare adverse reactions (occurring in less than 0.1% of patients) span multiple systems and include potentially serious events. Rare effects noted in regulatory labels include bronchospasm, the symptom of postural hypotension (dizziness upon standing), ocular disturbances like dry eyes, and dermatological effects such as alopecia and psoriasis exacerbation. Severe, rare effects reported are hepatotoxicity (liver damage) and agranulocytosis (a severe reduction in white blood cells).

Official Safety Constraints

The medicine is contraindicated and officially prohibited in individuals with pre-existing conditions such as sinus bradycardia, second or third-degree heart block, cardiogenic shock, or overt cardiac failure. For patients with renal impairment and older adults, the risk of adverse reactions is increased, and regulatory documents require dosage adjustments. A high-level safety constraint is that chronic therapy should not be discontinued abruptly due to the risk of exacerbation of certain cardiac conditions.

Overdose and Emergency Response

The official regulatory documents state that an overdose of Tenormin (atenolol) presents primarily as extensions of its pharmacological effects. The most serious documented manifestations of overdosage involve severe depression of the cardiovascular system, including symptomatic bradycardia (excessively slow heart rate) and profound hypotension (critically low blood pressure). Other life-threatening clinical signs documented are acute cardiac failure, the respiratory distress of bronchospasm, and metabolic disturbance leading to hypoglycemia.

Emergency medical help must be sought immediately if any manifestations of overdose occur, especially for severe conditions like symptomatic bradycardia or acute cardiac failure. The regulator-mandated initial response involves procedures to empty the stomach immediately, such as gastric lavage, and the rapid initiation of symptomatic and supportive treatment.

Specific interventions described in the label include the administration of IV Atropine or the use of a cardiac pacemaker for severe bradycardia, and the use of vasopressors or IV Glucagon for refractory hypotension. For patients with severe overdosage, hemodialysis may be used as a procedure to enhance the elimination of atenolol from the body. It is important to note that no specific antidote is named in the official treatment protocols.

Therapeutic Uses of Tenormin

What Tenormin Treats: Main Uses and Benefits

The primary purpose of Tenormin (atenolol) is generally used for cardiovascular regulation and antihypertensive management, offering supportive relief across key clinical areas. The medication is commonly used to help manage symptoms related to conditions like high blood pressure, angina (chest pain), and is considered relevant for long-term supportive care following a heart attack.

Therapeutic Applications and Patient Relief

This medicine is considered relevant in the long-term management of hypertension, and is applied in addressing symptoms related to chronic systemic strain caused by elevated pressure. Its use plays a role in managing symptoms related to systemic imbalance and may contribute to easing the systemic strain. It is also commonly applied for the prophylaxis of Angina Pectoris, addressing recurrent, episodic chest pain or pressure. The drug is relevant for easing symptoms related to heightened physiological activity, which includes complaints like palpitations and excessively rapid heartbeats.

“This supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.”

In clinical scenarios, Tenormin is relevant across conditions presenting with acute episodes and is commonly used for situations involving certain distressing symptoms or when functional stability becomes affected. This supports the management of chronic conditions presenting with systemic or localized discomfort.

Quick Fact: Relief for Recurrent Chest Discomfort

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Tenormin (atenolol) eligibility for use is strictly defined by regulatory bodies and is highly dependent on a patient's pre-existing cardiac function, age, and renal status. The medicine is primarily permitted for use in adults who are managing conditions like hypertension and angina.

Contraindications: Populations Who Must Not Use Tenormin

The drug is absolutely contraindicated in patients presenting with specific severe medical conditions:

  • Bradycardia (abnormally slow heart rate)
  • Second- or Third-Degree A-V Block (severe heart conduction issues)
  • Cardiogenic Shock or Overt Cardiac Failure
  • Untreated Pheochromocytoma (adrenal gland tumor)
  • Metabolic Acidosis or Severe Peripheral Arterial Circulatory Disturbances

Age and Reproductive Status Limitations

Population Regulatory Status
Children/Adolescents (Under 18) Use Not Established; Not Recommended
Pregnancy Restricted; Associated with fetal growth restriction and low birth weight
Lactation (Breastfeeding) Restricted; Excreted into breast milk; Caution required for infant monitoring

Condition-Based Restrictions

Conditional use is required in adults with impaired renal function. Since the drug is excreted by the kidneys, dose adjustments are mandatory when the creatinine clearance falls below 35 mL/min/1.73 m^2. Caution is also advised for patients with diabetes or thyroid conditions, as Tenormin may mask key signs of low blood sugar or hyperthyroidism.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Atenolol's interaction profile is primarily defined by its effects on heart function and its dependence on renal excretion, rather than major metabolic pathways. Government labeling describes specific pharmacodynamic and pharmacokinetic interactions.


Pharmacodynamic Interactions

Co-administration with certain medicinal products can lead to additive effects that slow heart rate and reduce blood pressure. Official labeling identifies the combination with specific Calcium Channel Blockers (e.g., Verapamil, Diltiazem) as carrying an increased risk of bradycardia and AV conduction delay. Similar additive effects may occur with other Antiarrhythmic Agents and Digitalis Glycosides. Additionally, Alcohol (Ethanol) may produce an additive effect in lowering blood pressure. The effects of the drug may be reduced by Prostaglandin Synthesis Inhibiting Drugs such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which exert a pharmacodynamic antagonism.


Absorption and Timing Restrictions

Substances that interfere with the absorption of the oral tablet form can reduce the drug's plasma concentration. Antacids containing aluminum hydroxide and Oral Calcium Salts officially reduce bioavailability, requiring that administration be separated by at least two hours from these products. A mandatory procedural constraint exists for combination therapy with Clonidine: Tenormin must be withdrawn gradually several days before the discontinuation of Clonidine to prevent the officially documented risk of rebound hypertension.


Clearance Considerations

The primary elimination route is through the kidneys. Consequently, official documents note that impaired renal function decreases clearance and prolongs the elimination half-life, which acts as a population-specific interaction consideration related to potential drug accumulation.

Mechanism of Action

Selective Modulation of Cardiac Beta-1 Receptors

The primary mechanism involves atenolol acting as a competitive antagonist, preferentially engaging beta1 adrenergic receptors found in the heart. This targeted action physically blocks stimulating hormones, such as norepinephrine, from binding, thereby reducing the stimulating effect of the sympathetic nervous system on the myocardium. This fundamental molecular blockade leads to the physiological outcome of negative chronotropy (slowing of the heart rate) and negative inotropy (reducing the force of heart contractions).


Influence on the Renal Neurohormonal Cascade

Atenolol also engages beta1 receptors located on the juxtaglomerular apparatus in the kidneys. This peripheral receptor blockade suppresses the release of renin, a key enzyme that initiates the complex Renin-Angiotensin-Aldosterone System (RAAS), a system that modulates blood vessel constriction and fluid volume. By modifying this early molecular step in the cascade, this mechanism alters the systemic regulation of peripheral vascular resistance.

Dosage and Administration Information

How Tenormin (Atenolol) is Used

The administration of Tenormin is defined by its two routes and corresponding use contexts. The primary mode of use is oral (tablet) for long-term therapeutic plans, taken typically once daily. The medication may be taken either with or without food. In contrast, the intravenous (I.V.) route is reserved for initial, acute medical scenarios, such as the early management phase following a myocardial infarction.


Official Dosing and Frequency Patterns

Standard oral dosing begins at an initial dose of 50 mg once daily for conditions like hypertension and angina pectoris. The maintenance dose is usually established between 50 mg and 100 mg once daily. For acute myocardial infarction, the intravenous phase involves administering two separate 5 mg doses over a 10-minute interval, followed by an oral transition dose soon after.


Population-Specific Use and Discontinuation

Standard protocols involve specific dose adjustments for certain patient groups. For older adults, a lower starting dose (e.g., 25 mg) may be necessary, and use in children is generally not recommended. The dose is significantly reduced in patients with renal impairment; for instance, those with severe kidney dysfunction (CrCl < 15 mL/min/1.73 m²) should not exceed 25 mg per day. Crucially, the medicine must not be stopped abruptly. Instead, the dosage requires gradual reduction over a period of one to two weeks to conclude therapy safely.


Administration Summary

Administration Type Typical Frequency Condition/Requirement
Oral Tablet Once Daily Swallowed whole; can be taken with or without food
Intravenous (I.V.) Injection Intermittent, Acute Use Administered slowly over a 5-minute period; requires hospital supervision

These instructions define the standardized, non-advisory protocol for using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tenormin (Atenolol)


Evidence for Use in High Blood Pressure (Hypertension)

Research examining Tenormin was studied for high blood pressure (hypertension) and primarily used Randomized Controlled Trials (RCTs) and large Meta-analyses. These studies were applied in research contexts involving adults with primary hypertension, often comparing Tenormin against placebo or other agents evaluated in trials for blood pressure. Researchers examined key outcomes monitoring physiological strain or stress, specifically monitoring changes in Systolic and Diastolic Blood Pressure (BP) over time.

Studies also monitored whether use was associated with patterns related to the occurrence of major Cardiovascular Events, such as the frequency of heart attacks and strokes. The follow-up durations for these major outcomes trials ranged from intermediate to long-term periods. Studies report how blood pressure levels evolved in the observed populations.

What remains uncertain is the extent of available long-term data for Tenormin when evaluated alongside other prescription agents regarding the long-term assessment of major events like stroke. The evidence highlights limitations in data when evaluating long-term outcomes, such as stroke, especially against certain agents evaluated more recently.


Evidence for Use in Chronic Stable Chest Pain (Angina Pectoris)

Tenormin was studied for chronic stable chest pain (Angina Pectoris) and the evidence base is mainly built upon short-term RCTs and controlled comparative studies. This research examined temporary physiological imbalance and was relevant in trials assessing short-term or episodic symptom patterns in populations of adults diagnosed with Chronic Stable Angina Pectoris.

Studies monitored outcomes related to physical discomfort, and research explored short-term symptom changes such as the frequency of chest pain episodes and the measured level of exercise capacity. The evidence contributes to the broader evidence landscape related to outcomes describing episodic or acute changes in this condition.


Evidence for Use Following a Heart Attack (Post-Myocardial Infarction)

Tenormin was evaluated in research for supportive care after a heart attack (Post-Myocardial Infarction) and the research foundation is built upon large-scale clinical trials which were applied in research contexts involving hemodynamically stable adults following an acute event. Research explored the frequency of both All-cause Mortality and Cardiovascular Mortality, as well as the occurrence of a Recurrent Myocardial Infarction.

What remains uncertain is the need for continued observation in patients whose heart function has recovered well, as long-term effects are not fully established or required in all observed patient groups. While evidence is available for early and intermediate-term use, the research is ongoing regarding the optimal duration of use in today's comprehensive cardiac care setting.

Key Studies & References

  1. Beta-blockers offer no clinical benefit for myocardial infarction survivors with preserved cardiac function (Meta-analysis Context)

Frequently Asked Questions (FAQ)

Common questions about Tenormin (FAQ)

Q: How long does Tenormin generally stay in a person’s system?

Official product information indicates that the elimination half-life of oral Tenormin is typically 6 to 7 hours. However, the full beta-blocking effect from a single dose can persist for at least 24 hours. This sustained effect is consistent with the medication's once-daily administration pattern.

Q: What is the key difference between Tenormin (atenolol) and Metoprolol?

Regulatory information describes Tenormin as water-soluble (hydrophilic), meaning it is primarily eliminated by the kidneys with minimal changes by the liver. In contrast, Metoprolol is fat-soluble (lipophilic) and is mainly broken down by the liver. This difference affects how the two medications are processed by the body.

Q: Is feeling extreme tiredness or fatigue a common, temporary, or long-term side effect of the drug?

Official public health guidance suggests that common side effects, such as fatigue or tiredness, are usually mild and short-lived. These effects often tend to wear off as the body adjusts to the medication, though individual experiences may vary.

Q: Are there specific symptoms of low blood pressure that users should be aware of?

Official documents note that symptoms associated with a drop in blood pressure (hypotension) can include dizziness, faintness, or lightheadedness when rising suddenly, or unusual tiredness or weakness while using the medicine.

Q: Does Tenormin have a common interaction with certain over-the-counter cold and cough medicines?

Yes, regulatory resources caution that combining Tenormin with sympathomimetic agents may cause an undesirable effect. These agents, which include ingredients like phenylephrine or caffeine, are often found in common cold and cough remedies and could potentially lead to an increase in blood pressure or heart rate.

Q: What happens if a dose of Tenormin is occasionally missed?

According to official product labeling, if you happen to miss a dose, the next dose should be taken as scheduled. It is specifically directed that a double dose not be taken.

Q: Is weight gain frequently reported by people who use Tenormin?

Official clinical trial data and adverse event reports categorize weight gain as either a rare effect or one where the incidence rate is not clearly determined in trials. It is not listed among the commonly occurring side effects.

Q: Can Tenormin cause sexual side effects, such as erectile dysfunction or decreased libido?

Official postmarketing reports list impotence (inability to have or keep an erection) as a rare adverse reaction. This type of sexual side effect has been observed, but with low frequency.

Q: Why are vivid dreams or nightmares sometimes associated with beta-blockers like Tenormin?

Official information describes Tenormin as having low lipid solubility and reduced ability to cross the blood-brain barrier compared to some other beta-blockers. This suggests potentially fewer effects on the central nervous system, although nightmares and vivid dreams are still reported as rare adverse effects.

Q: How does Tenormin affect the way the heart rate increases during exercise?

Official pharmacodynamics data state that Tenormin reduces both the resting heart rate and the rate at which the heart beats during exercise. The medication’s beta-blocking effect can be measured by monitoring the reduction in expected exercise heart rate (tachycardia) and overall cardiac output.

Q: Is Tenormin used to treat conditions other than high blood pressure and chest pain?

Yes, official therapeutic indications in various regulatory regions include the treatment of certain supraventricular and ventricular arrhythmias (irregular heart rhythms). It is also used for secondary prevention after an acute heart attack (myocardial infarction).

Q: Why might a physician advise a person to take Tenormin at night?

Public health guidance suggests that the first dose of Tenormin may be advised to be taken at bedtime. This timing is sometimes recommended because the medication can cause dizziness, which is often most noticeable when first starting treatment.

Q: Is Tenormin considered a blood thinner, an ACE inhibitor, or a diuretic?

According to the official description, Tenormin is classified as a beta-adrenergic receptor blocking agent, commonly known as a beta-blocker. It is a distinct class of medicine and is not classified as an ACE inhibitor, a diuretic, or a blood thinner.

Q: How is Tenormin's solubility (water-soluble) significant compared to other beta-blockers?

Official pharmacokinetic descriptions note that Tenormin is hydrophilic (water-soluble) and has low lipid solubility. This characteristic limits the amount of drug that crosses the blood-brain barrier, which is described in official documents as potentially limiting adverse effects on the central nervous system.

Q: Is there any information on Tenormin's potential for causing temporary hair loss?

Official adverse event reports classify hair loss (alopecia) as a rare adverse event. The condition is often described in these reports as being temporary in nature.

Q: What is the difference between immediate-release and extended-release forms of Tenormin?

The official FDA label lists Tenormin as available in oral tablets (immediate release) and an intravenous solution. The label does not list an official extended-release (ER) formulation for Tenormin (atenolol).

Q: Are there different restrictions for people with asthma using Tenormin versus other beta-blockers?

Official regulatory documents indicate that Tenormin is contraindicated, meaning its use is officially prohibited, in patients with severe asthma or severe chronic obstructive pulmonary disease (COPD). This is an important safety constraint related to respiratory conditions.

Q: Is there a specific mechanism by which Tenormin can affect sleep quality?

While sleep disturbances are reported as an uncommon side effect, official documents highlight the drug's hydrophilic nature. Its low brain penetrance is understood to limit central nervous system activity, but it does not prevent sleep issues entirely.

Q: Can the feeling of lightheadedness from Tenormin improve over the first few weeks of use?

Public health guidance regarding common adverse effects indicates that issues like dizziness and sleepiness may wear off as the body adjusts to the medication. These effects are often most noticeable when first starting treatment.

Q: Are there specific concerns for people with kidney problems who are prescribed Tenormin?

Official prescribing information states that Tenormin requires dosage adjustment when a person has impaired renal function. This is necessary because the drug is eliminated through the kidneys, and dose adjustments are described as being necessary based on measurements of creatinine clearance (CrCl) to prevent potential accumulation.

Q: Is there a difference in how Tenormin is used for high blood pressure versus chest pain (angina)?

According to the official dosage and indications information, the initial and maintenance oral dosing recommendations are typically the same for both high blood pressure and chronic stable angina pectoris. The standard starting dose is 50 mg once daily for both conditions.

Q: Are there any specific food items or beverages, other than alcohol, that can interact with Tenormin?

Yes, official interaction information notes that antacids containing aluminum hydroxide and Oral Calcium Salts can reduce the absorption of Tenormin. Official guidance indicates that administration of these products is typically separated by at least two hours. Some sources also note that caution is advised regarding the intake of caffeine.

How should Tenormin be stored and disposed of?

How to Store and Dispose of Tenormin (Atenolol)

Tenormin tablets must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). Storage must protect the product from light, excess heat, and moisture. The medication must be kept from freezing and should be stored in the original container, which must be kept tightly closed.

  • Child Safety: The product must be stored out of the sight and reach of children and pets.
  • Disposal: The medication must be thrown away after the expiration date. Users are officially instructed to ask a pharmacist or healthcare professional how to dispose of any unused or outdated medicine, often recommending the use of a medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tenormin found in:

A-Z Index: